Bulk Manufacturer of Controlled Substances Application: AMPAC Fine Chemicals Virginia, LLC, 45444 [R1-2020-16100]
Download as PDF
<![CDATA[
45444
Federal Register / Vol. 85, No. 145 / Tuesday, July 28, 2020 / Notices
39,130, 39,131 (2006); Dominick A.
Ricci, M.D., 58 FR 51,104, 51,105 (1993);
Bobby Watts, M.D., 53 FR 11,919, 11,920
(1988); Frederick Marsh Blanton, 43 FR
at 27,617.
According to California statute, ‘‘[n]o
person other than a physician . . . shall
write or issue a prescription.’’ Cal.
Health & Safety Code § 11150 (West
2020). Further, ‘‘physician,’’ as defined
by California statute, is a person who is
‘‘licensed to practice’’ in California. Id.
at § 11024.
Here, the undisputed evidence in the
record is that Registrant currently lacks
authority to practice medicine in
California. As already discussed, a
physician must be a licensed
practitioner to dispense a controlled
substance in California. Thus, because
Registrant lacks authority to practice
medicine in California and, therefore, is
not authorized to handle controlled
substances in California, Registrant is
not eligible to maintain a DEA
registration. Accordingly, I will order
that Registrant’s DEA registration be
revoked.
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a), I hereby revoke DEA Certificate
of Registration No. AS6936201 issued to
Frederick M. Silvers, M.D. Further,
pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
823(f), I hereby deny any pending
application of Frederick M. Silvers,
M.D. to renew or modify this
registration, as well as any pending
application of Frederick M. Silvers,
M.D. for registration in California. This
Order is effective August 27, 2020.
Timothy J. Shea,
Acting Administrator.
[FR Doc. 2020–16343 Filed 7–27–20; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–686]
khammond on DSKJM1Z7X2PROD with NOTICES
Bulk Manufacturer of Controlled
Substances Application: Ampac Fine
Chemicals LLC
Correction
Notice document 2020–16104,
appearing on page 44924 in the issue of
Friday, July 24th, 2020, was published
as a duplicate of notice document 2020–
16104 appearing on pages 44924–44925,
and is withdrawn. Notice document
2020–16100, which should have
VerDate Sep<11>2014
16:43 Jul 27, 2020
Jkt 250001
published Friday, July 24, 2020, is
republished elsewhere in this issue.
[FR Doc. C1–2020–16104 Filed 7–27–20; 8:45 am]
BILLING CODE 1301–00–D
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–683]
Bulk Manufacturer of Controlled
Substances Application: AMPAC Fine
Chemicals Virginia, LLC
Editorial Note: Notice document 2020–
16100, which should have published Friday,
July 24, 2020, did not appear in that issue.
We are republishing it here in its entirety.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before September 28, 2020.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on March 16, 2020,
AMPAC Fine Chemicals Virginia, LLC,
2820 North Normandy Drive,
Petersburg, Virginia 23805–2380,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
Methylphenidate ......
Levomethorphan ......
Levorphanol .............
Morphine ..................
Thebaine ..................
Noroxymorphone .....
Tapentadol ...............
1724
9210
9220
9300
9333
9668
9780
Schedule
By email .......
II
II
II
II
II
II
II
By mail .........
pubcomment-ees.enrd@
usdoj.gov.
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington, DC
20044–7611.
[FR Doc. R1–2020–16100 Filed 7–27–20; 8:45 am]
Frm 00076
Fmt 4703
Sfmt 4703
On July 21, 2020, the Department of
Justice lodged a proposed consent
decree with the United States District
Court for the District of Hawaii in the
lawsuit entitled United States v. Pacific
Energy South West Pacific, Ltd., Civil
Action No. 20–CV–322.
The United States filed this lawsuit
under the Clean Water Act. The United
States’ complaint seeks injunctive relief
and civil penalties for violations of a
National Pollutant Discharge
Elimination System permit, violations of
an administrative order issued by the
United States Environmental Protection
Agency, and unpermitted discharges of
pollutants to waters of the United States
at the American Samoa Terminal, a fuel
terminal that the defendant Pacific
Energy South West Pacific, Ltd.,
operates in Pago Pago, American Samoa.
The consent decree requires the
defendant to perform injunctive relief
and pay a $300,000 civil penalty.
The publication of this notice opens
a period for public comment on the
consent decree. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and should refer to
United States v. Pacific Energy South
West Pacific, Ltd., D.J. Ref. No. 90–5–1–
1–12086. All comments must be
submitted no later than thirty (30) days
after the publication date of this notice.
Comments may be submitted either by
email or by mail:
Send them to:
William T. McDermott,
Assistant Administrator.
PO 00000
Notice of Lodging of Proposed
Consent Decree Under the Clean Water
Act
To submit
comments:
The company plans to manufacture
the above-listed controlled substances
in bulk for distribution to its customers.
No other activities for these drug codes
are authorized for this registration.
BILLING CODE 1301–00–D
DEPARTMENT OF JUSTICE
During the public comment period,
the consent decree may be examined
and downloaded at this Justice
Department website: https://
www.justice.gov/enrd/consent-decrees.
We will provide a paper copy of the
consent decree upon written request
and payment of reproduction costs.
Please mail your request and payment
to: Consent Decree Library, U.S. DOJ—
ENRD, P.O. Box 7611, Washington, DC
20044–7611.
Please enclose a check or money order
for $11.50 (25 cents per page
E:\FR\FM\28JYN1.SGM
28JYN1
]]>Agencies
[Federal Register Volume 85, Number 145 (Tuesday, July 28, 2020)]
[Notices]
[Page 45444]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: R1-2020-16100]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-683]
Bulk Manufacturer of Controlled Substances Application: AMPAC
Fine Chemicals Virginia, LLC
Editorial Note: Notice document 2020-16100, which should have
published Friday, July 24, 2020, did not appear in that issue. We
are republishing it here in its entirety.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before September 28,
2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on March 16, 2020, AMPAC Fine Chemicals Virginia, LLC,
2820 North Normandy Drive, Petersburg, Virginia 23805-2380, applied to
be registered as a bulk manufacturer of the following basic class(es)
of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Methylphenidate....................... 1724 II
Levomethorphan........................ 9210 II
Levorphanol........................... 9220 II
Morphine.............................. 9300 II
Thebaine.............................. 9333 II
Noroxymorphone........................ 9668 II
Tapentadol............................ 9780 II
------------------------------------------------------------------------
The company plans to manufacture the above-listed controlled
substances in bulk for distribution to its customers. No other
activities for these drug codes are authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. R1-2020-16100 Filed 7-27-20; 8:45 am]
BILLING CODE 1301-00-D
